Conshohocken, Pa.-based pharmaceutical company Cencora plans to acquire the majority of the outstanding equity interests it does not currently own in OneOncology from TPG for approximately $3.6 billion, according to a Dec. 15 press release.
OneOncology is a physician-led platform that supports independent community oncology practices by providing shared infrastructure, data analytics, operational support and growth resources.The OneOncology network includes about 1,750 providers across more than 565 care locations nationwide.
The transaction, which values OneOncology at $7.4 billion, includes retiring $1.3 billion in existing corporate debt. Total cash consideration will be approximately $5 billion. Cencora expects the deal to close by the end of its fiscal 2026 second quarter, subject to regulatory approvals and customary closing conditions.
OneOncology’s affiliated practices and management will retain a minority stake following the deal.
